Simvastatin 40 mg tablets recalled for manufacturing practice deviations
Accord Healthcare is recalling 1,190,484 bottles of Simvastatin 40 mg tablets distributed in the United States, Puerto Rico, and Canada due to Current Good Manufacturing Practice deviations identified during an FDA inspection.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II classification indicates potential for adverse health consequences. This recall represents a risk-of-harm product where manufacturing control deviations have been identified but no illnesses or injuries have been reported, placing it at the High severity level per the rubric.
Plain-English summary
Accord Healthcare, Inc. is recalling 1,190,484 bottles of Simvastatin Tablets USP 40 mg across multiple batches. The recall follows an FDA inspection that identified Current Good Manufacturing Practice (CGMP) deviations at the manufacturing facility. These deviations relate to manufacturing and quality control procedures.
The affected product was distributed throughout the United States, including Puerto Rico, and Canada. The recall affects multiple batches with expiration dates ranging from February 2023 through May 2025. Affected batches are identified by specific lot numbers listed in the recall notice.
Consumers who have this medication should consult their healthcare provider about whether they should continue taking the product or switch to an alternative. Patients should not stop taking their medication without medical guidance. Those with questions about whether their medication is affected should check the lot number on their prescription bottle against the recall information.
The recalled product
- Product
- SIMVASTATIN (SIMVASTATIN)
- Brand
- SIMVASTATIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Batches: a) P2103713
- P2103692
- Exp. Date 5/31/2023
- P2104950
- P2104984
- P2104969
- P2104996
- P2105274
- P2105314
- P2105316
- Exp. Date 7/31/2023
- R2101074
- R2101077
- R2101078
- R2101079
- R2101083
- R2101084
- R2101117
- Exp. Date 8/31/2023
- R2101330
UPCs (2)
- 316729006156
- 316729006170
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · SIMVASTATIN
- HighPrescription Drug Simvastatin Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighAccord Healthcare Simvastatin 80 mg Tablets Recalled for Manufacturing Practice Violations
FDA (Drugs) · 2023-03-08
- ModerateSimvastatin tablets recalled due to manufacturing process deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27